<DOC>
	<DOCNO>NCT00255463</DOCNO>
	<brief_summary>The purpose study compare change proliferation biomarker subject receive Anastrozole Anastrozole/ZD1839 combination .</brief_summary>
	<brief_title>Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Measurable ( stage IIIIB ) non meta static non inflammatory breast cancer Patients must post menopausal woman opinion investigator would likely benefit endocrine therapy . Postmenopausal patient define : Natural menopause last menses &gt; 1 year ago , Radiation induce oophorectomy last menses &gt; 1 year ago , Serum FSH LH level clearly postmenopausal range institution . Bilateral oophorectomy Other current previous ( last 5 year ) malignancy , metastasis , abnormal blood chemistry , lung/ heart/kidney/liver abnormality , Hormonal treatment within last 2 week , previous hormonal treatment invasive cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>